Orphan Forecasts Meeting Xyrem Respiration Study Request By Year-End
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Orphan Medical expects to fulfill FDA's requirement for an acute exposure study of Xyrem (sodium oxybate) in respiratory-compromised patients by the end of 2001, the company said in a July 3 conference call.